4.7 Article

A phase I combination study of vigil and atezolizumab in recurrent/refractory advanced-stage ovarian cancer: Efficacy assessment in BRCA1/2-wt patients.

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 38, Issue 15_suppl, Pages 3002-3002

Publisher

American Society of Clinical Oncology (ASCO)
DOI: 10.1200/jco.2020.38.15_suppl.3002

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available